Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction interferon followed by peginterferon, ribavirin, and amantadine in treatment-naive chronic hepatitis C genotype 1 or 4
NL-OMON27278Active, not recruiting
- Sponsor
- Asan Medical Center Liver Center
- Start
- Jul 2002
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of interferon alfa, pegylated interferon alpha, ribavirin and amantadine in hepatitis C virus infection (2 arms), sponsored by Asan Medical Center Liver Center. Primary endpoint: Sustained virological response. Started Jul 2002; status: active, not recruiting.
02
Drugs
interferon alfapegylated interferon alpharibavirinamantadine
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON27278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27278.